Ultragenyx Reports Multiple 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, reported on July 24, 2026 the grant of 65,886 restricted stock units of the company's common stock to 39 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

Earlier in 2026, the company reported similar inducement grants. On June 19, 2026, Ultragenyx reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers, with a grant date of June 16, 2026. On May 22, 2026, the company reported the grant of 17,567 restricted stock units of the company's common stock to 11 newly hired non-executive officers, with a grant date of May 16, 2026. On April 24, 2026, the company reported the grant of 36,447 restricted stock units of the company's common stock to 12 newly hired non-executive officers, with a grant date of April 16, 2026. Each of these awards was granted under the Ultragenyx Employment Inducement Plan with the same four-year vesting schedule.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.